ArticleJACC. Case reports2025
One-Step Hybrid MIDCAB, Complex PCI, and TAVR in a 94-Year-Old Male With Early Cardiogenic Shock.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManagement of a complex multivessel disease with concomitant severe aortic stenosis remains clinically challenging, particularly in high-risk elderly patients. CASE SUMMARY: We describe the first known case of a nonagenarian with acute coronary syndrome and early cardiogenic shock who underwent a one-step hybrid minimally invasive direct coronary artery bypass, percutaneous coronary intervention, and transcatheter aortic valve replacement. The procedure was challenging and required unplanned escalation to extracorporeal membrane oxygenation support but was successfully performed with durable results at 1-year follow-up. DISCUSSION: The constant evolution in the management of combined structural heart and coronary artery disease provides new opportunities for alternative hybrid approaches that may better address patients with challenging comorbidities and prohibitively high surgical risk. TAKE-HOME MESSAGES: Hybrid coronary revascularization with combined transcatheter aortic valve replacement is a viable alternative in unacceptably high surgical risk patients. This case highlights the crucial role of a multidisciplinary heart team to accomplish excellent short- and long-term durable results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.